EPCAM Deletion Architecture Defines Distinct Cancer Phenotype
From JCO Precision Oncology Conversations · 28:39
Show by American Society of Clinical Oncology (ASCO)
JCO PO authors Dr. Kristin Kohler, Heather Hampel, and Dr. Michael Hall share insights into the JCO PO article, "Redefining the EPCAM Phenotype: Deletion Architecture Determines Lynch Syndrome Cancer Risk." Host Dr. Rafeh Naqash and guests discuss how the findings provide new insights into the molecular and clinical heterogeneity of germline deletions involving EPCAM. LINK TO FULL TRANSCRIPT
More episodes of JCO Precision Oncology Conversations
More episodes
- Pancreatic Imaging Findings in BRCA1/BRCA2/ATM/PALB2 Carriers
- Assessment of 2022 CMMRD Diagnostic Criteria
- JCO PO Article Insights: Tumor-informed ctDNA in Early Triple Negative Breast Cancer
- EMR-Based Nudge Improves Molecular Testing in Early-Stage NSCLC
- JCO PO Article Insights: CTCs as Biomarkers in GBM
- A Decade of Data: JCO PO and the TAPUR Study
- Introducing JCO Precision Oncology and Its Editor in Chief, Dr. James Ford
- Hyperthermic Intraperitoneal Chemotherapy–Induced Molecular Changes in Humans Validate Preclinical Data in Ovarian Cancer with Dr. Thanh Dellinger
- Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures with Dr. Mark Yarchoan
- Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors, with Dr. Mark Stewart
podsearch is a free, independent podcast search engine. Read about podsearch, the privacy policy or contact us.